Figures of funnel plots

Nonalcoholic fatty liver disease (NAFLD), a common chronic liver disease, has become one of the major global public health challenges. It has affected about 32.4% of adults and is being increased at an alarming rate over time. Unfortunately, there is no specific drugs approved to manage NAFLD at present. Silymarin, a common herbal agent, is a promising treatment choice for NAFLD due to its antioxidant, anti-inflammatory, and antifibrotic properties. However, it remains uncertain whether silymarin is efficacious in adults with NAFLD. We used standard, extensive Cochrane search methods. We included randomised clinical trials (RCTs) in adults with NAFLD comparing silymarin monotherapy or complex versus no intervention, placebo or other interventions to evaluate the benefits and harms of silymarin in adults with NAFLD.